Biomed SA

NEWS RELEASE: Formlabs Introduces Two New Materials for Dental and Medical Applications Dental LT Comfort Resin is a flexible, durable material for comfortable long-term occlusal splints, nightguards, and bleaching trays. Approved for human contact, BioMed Durable Resin allows for durable biocompatible and impact-resistant medical devices and instruments. Somerville, MA – June 13, 2023 – Formlabs , the leading 3D printing company, today announced two new materials for dental and medical applications available for the Form 3B, Form 3B+ , and Form 3BL printers: Dental LT Comfort Resin and Biomed Durable Resin . The company expands its library of over 40 3D printing materials to spark innovation and advance personalized patient care for point-of-care facilities, medical device makers, and dental and orthodontic practices and labs. “At Formlabs, we are continuously empowering our customers to push the boundaries in 3D printing,” said Guillaume Bailliard, President at Formlabs. “With the release of these two new materials, we’re proud to expand our material library and enable dental and healthcare professionals and engineers to push the boundaries of device development.” Dental LT Comfort Resin Formlabs introduces Dental LT Comfort Resin, a new durable and flexible material for long-term occlusal splints, nightguards, and bleaching trays. This new material was designed to provide patient comfort, fit, and durability against wear, in order to make a clinical impact, e.g., improving patient compliance to a treatment plan and requiring fewer patient follow-up visits. With this latest addition to Formlabs Dental’s comprehensive dental platform, the company is continuing its mission to provide superior, affordable, and easy-to-use materials to practices and labs. Dental LT Comfort Resin is optimal for comfortable long-term occlusal splints, nightguards, and bleaching trays. Dental and orthodontic labs, and dental practices can now directly print flexible splints that are long-term biocompatible, comfortable for the patient, and require minimal polish to reach high optical transparency for long-term use. With Dental LT Comfort Resin, dental practices can easily, efficiently, and economically scan patients and create a comfortable, superior surface finish splint within hours to lower costs and increase ROI. Below is the difference in lead time and costs for outsourced and in-house 3D printed occlusal splints: Cost for Single Occlusal Splint Lead Time Outsourced Production $100-$200 1-7 days In-House Production in Dental LT Comfort Resin $5-$7 2-3 hours “When I had the opportunity to beta-test the Dental LT Comfort from Formlabs Dental, I was amazed,” said Stephan Kreimer, Director of Kreimer Dentallabor GmbH & Co. KG. “The material’s pre-polished appearance and exceptional translucency right after printing significantly reduced post-processing time. Furthermore, I was impressed by its fracture resistance and flexibility, which ensure optimal comfort, making it the perfect choice for dental splints.” BioMed Durable Resin Formlabs biocompatible resins, including BioMed Clear Resin, BioMed White Resin, and more, have been widely used in healthcare applications from surgical guides to anatomical models. To meet demand for mass personalization and patient-specific devices, procedure-specific instruments, and medical devices, Formlabs now introduces BioMed Durable Resin, a new formulation developed specifically to address the need for a biocompatible material that can withstand impact, rough handling, and pressure. Patient-specific instruments (PSI) designed for unique patient anatomy have been shown to improve patient outcomes by 16% when using guides, reducing complications by almost 30%. In addition, personalized devices increase precision which lowers operating times and improves patient outcomes. BioMed Durable Resin will expand 3D printing in healthcare with impact-, shatter-, and abrasion-resistant properties and excellent clarity and surface finish, making it ideal for biocompatible and durable PSIs and customizable surgical instruments, such as medical devices that can be hit with a surgical mallet or shaken with a cutting saw. At TechFit, a PSI provider that works with physicians to design and 3D printed surgical instrumentation, CEO and co-founder Mauricio Toro uses BioMed Durable Resin to produce patient-specific instrumentation that is impact-, shatter-, and abrasion-resistant. “We see Biomed Durable Resin as an ideal platform for the printing of single-use, patient-specific surgical instrumentation,” said Toro. “The increased mechanical properties provide more design flexibility and increased indications while maintaining the biological properties required for reliably producing the best surgical results.” BioMed Durable Resin is a USP Class VI material, made in an FDA-registered, ISO 13485 facility and can be used in applications for long-term skin, and short-term tissue, bone, and dentin contact. Dental LT Comfort Resin (U.S. only) and BioMed Durable Resin are available now; visit to learn more. About Formlabs Formlabs is expanding access to digital fabrication, so anyone can make anything. Headquartered in Somerville, Massachusetts with offices in Germany, Japan, China, Singapore, Hungary, and North Carolina, Formlabs is the professional 3D printer of choice for engineers, designers, manufacturers, and decision makers around the globe. Formlabs products include the Form 3+, Form 3B+, Form 3L, and Form 3BL powered by an advanced form of stereolithography (SLA) called Low Force Stereolithography (LFS)™ 3D printing, Form Wash and Form Cure post-processing solutions, Fuse 1 SLS 3D printer, and Form Auto manufacturing solution. Through its Factory Solutions offering for industrial users, Formlabs provides the factories of tomorrow with the flexibility and versatility needed for demanding, evolving industrial applications. Formlabs also develops its own suite of high-performance materials that continue to push the boundaries for 3D printing, as well as best-in-class 3D printing software. For more information visit formlabs.com. The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.

Jeito Capital co-leads a EUR 104 million financing inNoema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders Noema Pharma's clinical-stage assets and diversified pipeline holdsignificant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS) disorders, addressing high unmet medical needs Jeito Capital's investment in Noema Pharma marks its second in the field ofneurological disorders and represents a significant opportunity to support this promising therapeutic area with high growth potential Through its investment, Jeito Capitalaims to promote the expansion and acceleration of Noema’s development activities andbolstervalue creation in France and in Europe,reinforcing its dedication to fostering the growth of biopharmaceutical champions in the region Paris, France, March 7th 2023 - Jeito Capital ("Jeito"), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has co-led a EUR 104 million (CHF 103 million, approx. USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. Noema Pharma has offices in Switzerland, France, and in the US. The oversubscribed financing was co-led by Jeito and Forbion with participation from new investors such as the UPMC Enterprises joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus. Founded in 2019 in Paris, France, Noema Pharma currently has multiple active Phase 2b clinical trials in highly undertreated CNS conditions including seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has also completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended to adolescents. As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders. Proceeds from the financing will primarily be used to advance the Company’s clinical-stage assets. Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential. As Jeito’s second investment in a biopharma company targeting neurological diseases, Noema Pharma's maturing clinical-stage pipeline shows great promise for helping patients who currently lack effective treatments or face unmet medical needs. In addition, Jeito will invest in Noema Pharma SAS (France), enabling it to expand its clinical trials and safety monitoring efforts in France and in Europe. This is expected to create new job opportunities and provide support for French and European suppliers in the manufacturing process. Rachel Mears, Partner at Jeito Capital, will join Noema Pharma’s Board of Directors. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented"We are excited to partner with Noema Pharma in their mission to accelerate the development of innovative treatments for debilitating CNS disorders. I am particularly proud that the company born in Paris three years ago, which developed in Switzerland and the US,continues to create value in France and Europe. This reflects Jeito Capital's strong commitment to fostering the emergence of potential global biopharma leaders from Europe.As Jeito Capital's second investment in a neurology company, Noema Pharma with its clinical-stage assets and diversified pipeline hasshown significant potential for the development of effective innovativetherapiesfor the benefit of patients." Rachel Mears, Partner at Jeito Capitaladded: “One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need. The clinical work being undertaken by Noema Pharma fit these criteria exactly. The expertise, quality and dedication of the Noema team are clear to see in their development work and position the Company as an upcoming global CNS leader. We are excited to partner with Noema Pharma to accelerate its mission of developing effective solutions for patients with CNS disorders and are committed to supporting their continued growth and success." Luigi Costa, Chief Executive Officer of Noema Pharma said:“We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.” About Jeito Capital Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. @Jeito_lifeLinkedInFor more information, please visit or follow @Jeito_life on Twitter or LinkedIn. About Noema Pharma Noema Pharma ( ) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor. Jeito Capital Rafaèle Tordjman, Founder & CEO Assia Mouhout, EA Tel : +33 6 76 49 37 94 Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam Jeito@consilium-comms.com Tel: +44 (0) 20 3709 5700 Marion Bougeard marion@achto-conseil.fr Tel : +33 6 76 73 57 31

Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders Nanna Lüneborg, General Partner at Forbion and Rachel Mears, Partner at Jeito Capital to join Board of Directors Multiple Phase 2b trials in orphan and mainstream CNS indications continue to advance BASEL, Switzerland, March 07, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 million (approx. USD 112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus to complete the round. Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma. The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The Company is also developing gemlapodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder. "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders," said Luigi Costa, Chief Executive Officer of Noema Pharma."We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.“ "We have been following Noema since inception and have been impressed by the quality and progress of Noema Pharma’s clinical pipeline. We believe this is the right time to invest as the Company has started to generate very encouraging clinical data in indications of high unmet need and particularly with its lead asset basimglurant. We are therefore delighted to back Noema from our second Growth Opportunities Fund which focuses on investments in late-stage European drug development companies. We believe Noema to be at the forefront of a significant new wave of innovation in the field of central nervous system disorders which impact millions globally" explained Nanna Lüneborg, General Partner at Forbion. "One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need," said Rachel Mears, Partner at Jeito Capital. "The research and clinical work being undertaken by Noema Pharma fit these criteria exactly. The dedication of the Noema team and the quality of their work is clear to see and positions the company as the upcoming global leader in its field." “As co-founders and initial investors of Noema Pharma, we are incredibly proud of what the company has accomplished since its inception,” said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners. “Raising an oversubscribed funding round of this magnitude is a significant achievement, that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders." The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche. About Noema Pharma Noema Pharma ( ) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor. Contacts Noema Pharma Michael Gutch, PhD Chief Financial Officer info@noemapharma.com Investors LifeSci Advisors – Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 (0) 76 735 01 31